Merck & Company Buy Rating Justified by Keytruda’s Performance and Gardasil’s Market Potential
Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).
BioPharma Dive2d
ADC developed by Daiichi, Merck outperforms chemo in lung cancer trial
The FDA previously rejected patritumab deruxtecan over manufacturing issues. Tuesday's study data should boost the companies' case, however.
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
The gross proceeds to the Company from the exercise of the Existing Warrants together with the sale of the new warrants is expected to be approximately $6.2 million. The closing of the transaction is ...
Finanznachrichten4mon
Eisai Accelerates Progress In Oncology Research With New Data At Esmo Congress 2024
plus pembrolizumab (KEYTRUDA(R)), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, in combination withtransarterial chemoembolization (TACE) for the treatment of patients with unresectable, ...